DBV Technologies (DBVT) Common Equity (2014 - 2026)
DBV Technologies (DBVT) reported Common Equity of $207.9 million for Q1 2026, up 7068.97% year-over-year from $2.9 million in Q1 2025, and up 23.16% on a QoQ basis from $168.8 million in Q4 2025.
DBV Technologies (DBVT) has 13 years of Common Equity data on file, last reported at $207.9 million in Q1 2026.
- Quarterly Common Equity rose 7068.97% year-over-year to $207.9 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $207.9 million (up 7068.97% YoY) and the FY2025 annual result came in at $168.8 million, up 516.06% from the prior year.
- Common Equity advanced to $207.9 million in Q1 2026 per DBVT's latest filing, from $168.8 million in the prior quarter.
- Across five years, Common Equity topped out at $244.4 million in Q2 2022 and bottomed at $2.9 million in Q1 2025.
- The 5-year median for Common Equity is $140.2 million (2023), against an average of $126.6 million.
- The widest annual swing landed in 2025, when Common Equity sank 97.4%; it then jumped 7068.97% in 2026.
- Tracing DBVT's Common Equity over 5 years: stood at $194.5 million in 2022, then slipped by 27.91% to $140.2 million in 2023, then slumped by 80.45% to $27.4 million in 2024, then jumped by 516.06% to $168.8 million in 2025, then grew by 23.16% to $207.9 million in 2026.
- Per Business Quant, the three latest DBVT Common Equity figures stand at $207.9 million (Q1 2026), $168.8 million (Q4 2025), and $52.9 million (Q3 2025).
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Common Equity (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 961,148.99 Bn | 961,148.98 Bn | - | -1.42 Mn |
| 2 | Alterity Therapeutics | 744,933.29 Bn | 744,933.26 Bn | - | 35.63 Mn |
| 3 | Legend Biotech | 2,540.00 Bn | 2,539.71 Bn | 242.10 Mn | 1.00 Bn |
| 4 | Nanobiotix | 2,199.85 Bn | 2,199.78 Bn | - | - |
| 5 | Akari Therapeutics | 1,635.88 Bn | 1,635.88 Bn | - | 14.38 Mn |
| 6 | Vertex Pharmaceuticals | 111.32 Bn | 104.07 Bn | 2.59 Bn | 19.36 Bn |
| 7 | Evaxion A | 62.56 Bn | 62.54 Bn | - | 13.21 Mn |
| 8 | Regeneron Pharmaceuticals | 62.55 Bn | 53.79 Bn | 3.31 Bn | 31.42 Bn |
| 9 | Alnylam Pharmaceuticals | 39.57 Bn | 36.56 Bn | 959.66 Mn | 1.08 Bn |
| 10 | DBV Technologies | 8.00 Bn | 7.77 Bn | -3.90 Mn | 207.90 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 207.90 Mn |
| Dec 31, 2025 | 168.80 Mn |
| Sep 30, 2025 | 52.85 Mn |
| Jun 30, 2025 | 86.22 Mn |
| Mar 31, 2025 | 2.90 Mn |
| Dec 31, 2024 | 27.40 Mn |
| Sep 30, 2024 | 54.03 Mn |
| Jun 30, 2024 | 79.10 Mn |
| Mar 31, 2024 | 111.65 Mn |
| Dec 31, 2023 | 140.19 Mn |
| Sep 30, 2023 | 143.99 Mn |
| Jun 30, 2023 | 164.24 Mn |
| Mar 31, 2023 | 179.09 Mn |
| Dec 31, 2022 | 194.45 Mn |
| Sep 30, 2022 | 212.05 Mn |
| Jun 30, 2022 | 244.42 Mn |
| Mar 31, 2022 | 82.06 Mn |
| Dec 31, 2021 | 99.27 Mn |
| Sep 30, 2021 | 116.89 Mn |
| Jun 30, 2021 | 143.02 Mn |
| Mar 31, 2021 | 169.18 Mn |
| Dec 31, 2020 | 205.49 Mn |
| Sep 30, 2020 | 233.10 Mn |
| Jun 30, 2020 | 251.74 Mn |
| Mar 31, 2020 | 299.66 Mn |
| Dec 31, 2019 | 5.21 Mn |
| Sep 30, 2019 | 4.02 Mn |
| Jun 30, 2019 | 4.06 Mn |
| Dec 31, 2018 | 3.44 Mn |
| Jun 30, 2018 | 3.58 Mn |
| Dec 31, 2017 | 2.94 Mn |
| Jun 30, 2017 | 2.72 Mn |
| Dec 31, 2016 | 2.66 Mn |
| Jun 30, 2016 | 2.78 Mn |
| Dec 31, 2015 | 353.03 Mn |
| Jun 30, 2015 | 2.17 Mn |
| Dec 31, 2014 | 144.29 Mn |